ABC Medical Center > BCR/ABL MUTATION (RESIST. INHIBIT TYROSINKINASE)

BCR/ABL MUTATION (RESIST. INHIBIT TYROSINKINASE)

Indications:

No special indications

What it's for:

Evaluation of patients with chronic myelogenous leukemia and Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia receiving treatment with tyrosine kinase inhibitors (TKIs), who are apparently failing treatment. Preferred initial test to identify the presence of acquired BCR-ABL1 mutations associated with TKI resistance.

Delivery time:

10 business days

How can we help you?

    Index

    Content